COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk / World Health Organization (WHO)

SARS-COV-2 (virus Responsible of COVID-19) Reinfection and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk: Matched Case-control Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06255860

Acronym

REPI

Enrollment

204

Registered

2024-02-13

Start date

2023-09-22

Completion date

2024-04-01

Last updated

2024-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MIS-C, Sars-CoV-2 Infection

Brief summary

This study is a multicenter, international, non interventional, retrospective study about SARS-CoV-2 and Multisystem Inflammatory Syndrome (MIS-C) reinfection risk in children.

Detailed description

This study is based to data collection of cases (patients with MIS-C) compare to controls (patients with SARS-CoV-2 infection) occurring between 01 sep 2021 and 30 apr 2022. For this study cases and controls group will be matched for analyses. The main of this study is to evaluate the difference of risk of occurrence of MIS-C between a first SARS-CoV-2 infection and a reinfection with SARS-CoV-2.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Days to 18 Years

Healthy volunteers

Yes

Inclusion criteria

group 1: cases * Patients with MIS-C (following SARS CoV-2 infection) * Hospitalised between the 01 sep 2021 and 30 apr 2022 * Under 18 years of age * Not vaccinated for SARS-CoV-2 group 2: controls * Patients not hospitalised, treated by outpatient care * With documented SARS-CoV-2 infection between the 01 sep 2021 and 30 apr 2022 * Matched with a case on age (+/- 6 months), gender and country * Not vaccinated for SARS-CoV-2

Exclusion criteria

\- Refusal to participate by patient relative or legal representative

Design outcomes

Primary

Measure	Time frame	Description
proportion of MIS-C cases occurred after first SARS-CoV-2 infection	8 months	Assessment of risk of MIS-C after first SARS-CoV-2 infection
proportion of MIS-C cases occurred after SARS-CoV-2 reinfection	8 months	Assessment of risk of MIS-C after SARS-CoV-2 reinfection
Proportion of SARS-CoV-2 reinfection after first SARS-CoV-2 infection	8 months	Assessment of risk of SARS-CoV-2 reinfection after first SARS-CoV-2 infection

Countries

France

Outcome results